In the U.S. alone, more than 32 million people suffer from food allergies — a number that’s only growing. Many allergies are life threatening, and there is no cure. Testing is crucial to determine their presence, severity and treatment. But until now, the available testing options have had drawbacks for both patients and clinicians.
Kenota is decentralizing allergy testing with a proprietary approach that employs rapid, point of care instrumentation. Capable of swiftly quantifying a patient’s sensitization to allergens, our system is compact, streamlined and can be administered easily by allergists and their staff.
Designed with allergists in mind
Uncovers sensitizations with a few drops of blood
Easy to administer: results and reports generated on the spot
Allergists can provide end-to-end care in a single visit – no need for lab referrals
From the outset, we’ve had an unwavering vision: to change allergy testing to deliver a better system for allergists and a better experience to patients. Here are some highlights of our journey so far:
Developed concept for in-clinic allergy testing system
Completed FDA pre-submission and developed functioning prototypes
Established scalable 33,000 square-foot manufacturing facility in Waterloo Region, Canada
Created pilot systems and conducted successful allergy clinic pilot study
Raised $11 million in Series A funding
Kenota Health is an entrepreneurially minded team with deep scientific, clinical and commercial expertise. An idea first sparked in the tech hotbed of Waterloo Region has grown into a team of passionate and innovative professionals, collectively focused on elevating healthcare through the world’s best data and testing technology.
